Depression

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Citadel, Depression, Department of Defence, National War College, Legislation, Government, Army Command, Veteran, Veterans' affairs, General counsel, Patient, Insomnia, Colonel, TBI, Policy, Senior counsel, University, Anxiety, Military personnel, Military, Traumatic brain injury, OGC, National Security Strategy, Private law, PTSD, Nursing

HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”).

Key Points: 
  • HOUSTON, TEXAS, April 02, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of former Acting General Counsel to the Department of Veterans Affairs, William (“Bill”) A. Hudson, Jr., to the Company’s Military & Government Advisory Board (“Advisory Board”).
  • Nexalin’s Advisory Board provides strategic advice and counsel to support the Company’s advancement of its non-invasive, frequency-based, deep-brain stimulation devices in U.S. military and government agencies.
  • Mr. Hudson is a partner in Tully Rinckey PLLC’s Washington, D.C. office where he focuses his practice on military, security clearance, and federal employment law.
  • Mark White, CEO of Nexalin Technology stated, “We are honored to welcome Col. Bill Hudson to the Military & Government Advisory Board.

Child Abuse and Sex Trafficking: What You Might Not Know

Retrieved on: 
Tuesday, April 2, 2024
Depression, Psychological abuse, Substance abuse, Abuse, Child abuse, Anxiety, Hope, Polaris, Molina Healthcare, DCF, Statistics, Physical abuse, Survivor, Social services, Ecosystem, Curriculum, NCMEC, Toy

This month serves as a powerful reminder that child abuse prevention is not a solitary effort.

Key Points: 
  • This month serves as a powerful reminder that child abuse prevention is not a solitary effort.
  • On a state level, the statistics for child abuse in Florida in 2023 show concerning trends with reported cases on the rise.
  • Child abuse and sex trafficking are closely related, with child sex trafficking being a form of child abuse that occurs when a child under 18 is advertised, solicited, or exploited through a commercial sex act.
  • It is crucial to raise awareness about these interconnected challenges during Child Abuse Awareness Month and recognize the shared vulnerabilities that contribute to these forms of exploitation.

Park Aerospace Corp. Celebrates 70 Years In Business

Retrieved on: 
Monday, April 1, 2024
Depression, Tax, AFP, Unmanned aerial vehicle, Risk, Bridge, Mediocre, Park Aerospace Corp, WWI, PPP, Judgement

NEWTON, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Park Aerospace Corp. (NYSE-PKE) celebrates 70 years in business.

Key Points: 
  • NEWTON, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Park Aerospace Corp. (NYSE-PKE) celebrates 70 years in business.
  • Park was founded 70 years ago on March 31, 1954 by Jerry Shore, Brian Shore’s father, and Tony Chiesa, our very dear and special life-long friend.
  • Thank you, Jerry and Tony.”
    Park Aerospace Corp. develops and manufactures solution and hot-melt advanced composite materials used to produce composite structures for the global aerospace markets.
  • As a complement to Park’s advanced composite materials offering, Park designs and fabricates composite parts, structures and assemblies and low volume tooling for the aerospace industry.

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

Retrieved on: 
Monday, April 1, 2024
Neuroplasticity, Stroke, Diagnosis, Depression, Plasma, CHDR, Rat, Patient, Research, Biomarker, DMT, AGN, Ifenprodil, Brain, Clinical trial, Safety, Algernon, USD, Pharmaceutical industry

Algernon established Algernon NeuroScience (AGN Neuro), a wholly owned subsidiary, to advance the research and development of the DMT stroke program in 2023.

Key Points: 
  • Algernon established Algernon NeuroScience (AGN Neuro), a wholly owned subsidiary, to advance the research and development of the DMT stroke program in 2023.
  • AGN Neuro has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2a DMT Stroke study.
  • The Phase 2a human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
  • “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”
    Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo.

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Retrieved on: 
Thursday, March 28, 2024
Research, Depression, Congress, PD, Patient, OUD, CIAS, Sale, G&A, DMT, Șaeș, Pivotal, Psilocybin, Atai, TRD, Investment, Ibogaine, Pharmacokinetics, Safety, PTSD, OTF, Pharmaceutical industry

“In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.

Key Points: 
  • “In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need.
  • In November 2023, atai acquired all remaining outstanding shares of its subsidiary, DemeRx IB, Inc., streamlining clinical, general and administrative operations.
  • atai realized operational efficiencies by simplifying and optimizing its organizational structure in line with its revised business and pipeline priorities.
  • In August 2023, the Phase 1 study results demonstrated that 9 mg/kg of oral ibogaine leads to robust psychedelic experiences.

BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis

Retrieved on: 
Thursday, March 28, 2024
Depression, Deep, Brainsway, Medicine, Safety, MDD, Patient, Ageing, TMS, Journal, Doctor of Philosophy, DSM-IV codes, Efficacy, Mixed anxiety–depressive disorder, Atrophy, Scalp, FDA, Pharmaceutical industry

The post-marketing study demonstrated real-world outcomes for older adults (60-91 years of age) suffering from major depressive disorder (MDD).

Key Points: 
  • The post-marketing study demonstrated real-world outcomes for older adults (60-91 years of age) suffering from major depressive disorder (MDD).
  • In the study, data was analyzed from 247 depression patients at 16 clinical sites in this age group who had been treated with BrainsWay’s proprietary H1 Coil.
  • The outcomes were comparable to those reported in a post-marketing analysis of over 1,350 patients published in 2023.
  • This can make it challenging for certain non-invasive technologies to reach the brain areas involved in depression,” said Colleen Hanlon, PhD, Vice President of Medical and Clinical Affairs at BrainsWay.

Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group

Retrieved on: 
Wednesday, March 27, 2024
Depression, Neuropsychiatry, Partner, Psychiatry, ADHD, Mental, Partnership, LMHC, Transcranial magnetic stimulation, TMS, News, Acquisition, Brain, Region, Physician, Health, Dementia, Practitioner, Nursing

"We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.

Key Points: 
  • "We are thrilled to have joined Beacon Behavioral Partners and expand throughout the state," says Dr. Faizi Ahmed, the leading physician at Neuropsychiatry and TMS Group.
  • Established in 2016, The Neuropsychiatry & TMS Group, led by Dr. Ahmed, has been dedicated to delivering exceptional mental health services.
  • With the support of Beacon, The Neuropsychiatry & TMS Group anticipates continued growth opportunities, including expanding its TMS services and recruiting additional physicians.
  • “I am pleased to announce our recent expansion into Florida, a natural progression for Beacon,” says Beacon Behavioral Partners CEO Sean Wendell.

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Retrieved on: 
Wednesday, March 27, 2024
Patent Cooperation Treaty, Depression, Selective serotonin reuptake inhibitor, Obesity, CWY, Patent, Central nervous system, SSRI, Patient, DSM-IV codes, Mental health, Anxiety, Therapy, USD, Pharmaceutical industry

Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Key Points: 
  • The patent applications refer to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression.
  • This application was previously filed as provisional patent application with the United States Patent and Trademark Office (“USPTO”).
  • Under our collaboration with SciSparc, we believe that our proprietary drugs can positively impact patients dealing with various forms of depression including treatment resistant depression," stated Dr. Adi Zuloff-Shani, CEO of Clearmind.
  • "We further believe that we have a tremendous opportunity to develop viable alternatives to the current SSRIs for individuals living with depression.

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

Retrieved on: 
Wednesday, March 27, 2024
Patent Cooperation Treaty, Depression, Obesity, CWY, Central nervous system, DSM-IV codes, Anxiety, Patent, Therapy, Disorder, USD, TEL, Pharmaceutical industry

TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty.

Key Points: 
  • TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty.
  • The patent application refers to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression.
  • According to the ResearchAndMarkets.com , the global depression and anxiety disorders treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Overall, as part of this collaboration, nine other patent applications have been filed by Clearmind with the USPTO for various compositions, including the composition of SciSparc’s CannAmide™with Clearmind’s MEAI compound for the treatment of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Retrieved on: 
Wednesday, March 27, 2024
Depression, Headache, Atypical depression, Data analysis, Patient, Aes, Trial of the century, Nausea, TRD, Treatment, Safety, Vomiting, Pharmaceutical industry

The open-label Phase 2a study investigated the safety, tolerability and efficacy of a single 10mg dose of BPL-003 alongside psychological support in patients with moderate-to-severe TRD who were not taking concomitant antidepressants.

Key Points: 
  • The open-label Phase 2a study investigated the safety, tolerability and efficacy of a single 10mg dose of BPL-003 alongside psychological support in patients with moderate-to-severe TRD who were not taking concomitant antidepressants.
  • Patients were followed for 12 weeks post-dosing, with assessments conducted at multiple points throughout the study.
  • Initial analysis showed that a single dose of BPL-003 induced a rapid antidepressant response2 in 55% of patients on the day after dosing.
  • The positive data from the Phase 2a study is highly encouraging as we await the results of the larger Phase 2b study anticipated later this year.